• 3 ASX 200 dividend shares that just upped their payouts

    Man putting in a coin in a coin jar with piles of coins next to it.

    Earnings season has continued this Thursday, with a cavalcade of S&P/ASX 200 Index (ASX: XJO) shares reporting their latest numbers to investors. Many of them have also revealed the next dividend their investors can look forward to. So today, let’s go over three prominent blue-chip ASX 200 dividend shares and check out what kind of income is coming investors’ way.

    Three ASX 200 dividend shares that just boosted their payouts

    South32 Ltd (ASX: S32)

    Mining stock and ASX 200 dividend share, South32, is first up. The miner had some impressive numbers to show off this morning. Although revenues were only up 1% to US$5.82 billion, underlying earnings grew 38% to US$2.46 billion. Profits after tax attributable to members roared higher, jumping 410% to US$1.09 billion.

    That all helped South32 to declare a final dividend of 5.4 US cents per share. Like most payouts from this ASX 200 dividend share, this one will come with full franking credits attached.

    This new final dividend is more than double what investors bagged this time last year, up 107.7% over 2025’s final dividend of 2.6 US cents per share. Right now, South32 shares are trading on a trailing dividend yield of 1.81%.

    Qantas Airways Ltd (ASX: QAN)

    Since the resumption of Qantas’ shareholder payouts last year, the airline has become a favourite ASX 200 dividend share amongst income investors. That trend continues into the back half of 2026. This morning, Qantas revealed a final dividend of 19.8 cents per share, fully franked.

    That matches 2026’s interim dividend, and represents a 20% hike over 2025’s final ordinary payout of 16.5 cents per share.

    This came despite Qantas also reporting an underlying profit before tax of $2.06 billion, down 11.82% from 2025. The national carrier’s earnings per share (EPS) also fell 12.73% to 96 cents.

    Qantas stock is currently trading with a dividend yield of 3.8%.

    Wesfarmers Ltd (ASX: WES)

    Finally, let’s talk about ASX 200 dividend share and popular blue chip, Wesfarmers. The Bunnings, Kmart, OfficeWorks, and Target owner also dropped its report today. There were lots of green numbers on display.

    For FY2026, Wesfarmers reported revenue of $47.27 billion, up 3.4% year on year. Earnings before interest and tax excluding significant items rose 7.3%, while statutory net profits after tax (excluding significant items) jumped 8.3% to $2.87 billion.

    That enabled Wesfarmers to declare a fully-franked final dividend of $1.20 per share. That represents an 8.11% rise over last year’s equivalent payout of $1.11 per share.

    Wesfarmers is presently sitting on a dividend yield of 2.68%.

    The post 3 ASX 200 dividend shares that just upped their payouts appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Qantas Airways right now?

    Before you buy Qantas Airways shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Qantas Airways wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Sebastian Bowen has positions in Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Nvidia shares jump after earnings report. Here’s what has investors excited

    Flag of USA on a processor, CPU Central processing Unit, or GPU microchip on a motherboard.

    Nvidia Corp (NASDAQ: NVDA) shares are moving higher in after-hours trading after the chip giant released another monster quarterly result.

    The Nvidia share price finished Wednesday’s regular session down 1.59% at US$209.66, but quickly turned around after the result.

    At the latest check, the shares were up 4.71% after hours to US$219.53.

    The quarterly numbers were strong, but it was management’s longer-term outlook that really caught investors’ attention.

    Let’s take a closer look at the numbers.

    Another huge quarter

    Nvidia reported second-quarter revenue of US$96.2 billion, up 18% from the previous quarter and 106% from a year earlier.

    That comfortably beat Wall Street expectations of around US$92.3 billion.

    Adjusted earnings came in at US$2.22 per share, also ahead of the US$2.09 analysts were expecting.

    Once again, Data Center did most of the heavy lifting. Revenue from the division reached US$89 billion, up 117% year on year and representing more than 90% of total sales.

    CEO Jensen Huang said AI had “reached its inflection point”, adding that demand continued to accelerate as more AI labs, cloud providers, and businesses increased spending.

    The company’s next-generation Vera Rubin platform is also moving into full production, with systems already running at major cloud partners.

    The company also returned around US$26 billion to shareholders through share buybacks and dividends during the quarter.

    What stood out?

    While the quarterly result was impressive, the biggest talking point came during the earnings call.

    Management said it expects revenue to grow by around 70% in fiscal 2028, well ahead of the roughly 45% growth Wall Street had been expecting.

    What makes that outlook even more interesting is that Nvidia is still struggling to keep up with demand. The company indicated it can currently meet only around 70% of demand, with supply still falling short.

    WAM Global analyst Laura Hargrove said the one-year guidance “signals confidence in the durability of demand for AI chips”.

    She also pointed out that demand is becoming broader, with enterprise customers, sovereign AI programs, and specialised cloud providers accounting for a growing share of revenue.

    Investors clearly liked what they heard, with Nvidia shares climbing more than 4% in after-hours trading.

    There was also plenty to like in the near-term outlook.

    Nvidia expects third-quarter revenue of around US$108 billion, ahead of Wall Street estimates of roughly US$104 billion.

    What should investors watch?

    There are still a few areas worth keeping an eye on.

    Gross margins are expected to slip slightly from 75% to around 74% in the third quarter as memory and component costs rise.

    Management also expects margins to fall further later in the year before starting to recover.

    So, if you own Nvidia shares, it’s worth seeing how this metric tracks over the next few quarters.

    The post Nvidia shares jump after earnings report. Here’s what has investors excited appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Nvidia right now?

    Before you buy Nvidia shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Nvidia wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Nvidia. The Motley Fool Australia has recommended Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares

    A financial expert or broker looks worried as he checks out a graph showing market volatility.

    S&P/ASX 200 Index (ASX: XJO) shares are down 0.9% to 9,049.3 points on Thursday.

    Among the 11 market sectors of the ASX 200, healthcare is the only one in the green, up 0.3%.

    As earnings season continues, brokers are busy updating their ratings.

    Let’s check out some new recommendations.

    Neuren Pharmaceuticals Ltd (ASX: NEU)

    This ASX healthcare share is $20.60 apiece, up 2.2% today and up 8% over 12 months.

    Bell Potter reiterated its buy rating on Neuren Pharmaceuticals shares after the company’s 1H FY26 report.

    Neuren Pharmaceuticals announced a maiden fully-franked interim dividend of 15 cents per share.

    The broker kept its 12-month share price target at $25.50. 

    This implies potential capital gains of almost 25% ahead.

    Analyst Thomas Wakim said:

    The dividend provides a moderate yield for shareholders, however capital growth will dominate future shareholder returns and is the reason to own the stock in our view, particularly as the binary Phase 3 readout in PMS draws closer (estimated in ~1H CY28), the result of which will largely determine whether NEU is a one-trick pony or whether they repeat the glory a second time round with NNZ-2591.

    Whitehaven Coal Ltd (ASX: WHC)

    The Whitehaven Coal share price is $8.10, up 0.4% today and up 19% over 12 months.

    Morgans downgraded its recommendation from buy to hold due to recent share price strength.

    After reviewing the miner’s FY26 results, the broker reduced its 12-month target from $8.50 to $8.05.

    This implies the ASX 200 energy share is already fully valued.

    Morgans commented:

    WHC delivered a mixed result, with EBITDA broadly in line with consensus expectations, although underlying NPAT missed slightly.

    A 6c dividend was declared, consistent with consensus.

    The effects of poor coal prices in the 1H provided a significant headwind for the full-year result.

    FY27 guidance was softer than expected, with production growth appearing limited given the unchanged upper end of group guidance, while both costs and capital expenditure expectations have moved higher.

    Endeavour Group Ltd (ASX: EDV)

    The Endeavour share price is $3.05, down 0.5% today and down 23% over 12 months.

    Morgans maintained a trim call on the ASX 200 consumer staples share after Endeavour’s FY26 report.

    The broker cut its target price from $3.20 to $2.95, suggesting a 3% downside ahead.

    Morgans said:

    There were no major surprises in EDV’s FY26 result after the company pre-announced its key numbers (sales, underlying EBIT and underlying NPAT) in early August.

    However, the outlook for costs was greater than anticipated as EDV increases investment to execute its new strategy.

    Management noted that competition remains intense in the Retail segment, particularly in the online channel, while Hotels sales growth softened in early 1H27 across all key categories (food & beverage, gaming and accommodation).

    We expect FY27 to be a disruptive year as EDV implements its transformation initiatives.

    Liquor demand also remains under pressure from elevated interest rates, ongoing cost-of-living pressures and a subdued consumer environment.

    Given these headwinds and the execution risk associated with the transformation program, we believe the balance of risks remains skewed to the downside.

    The post Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Neuren Pharmaceuticals right now?

    Before you buy Neuren Pharmaceuticals shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuren Pharmaceuticals wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.